Drug intelligence / Profile preview

AMP-203

Development stage: Unknown
Lead developer: Amplifica Holdings Group
Modality: Peptides, Small Molecules
Administration: Topical

Overview

AMP-203 is an investigational compound being developed by Amplifica Holdings Group as a potential treatment for hair loss. As of June 2023, Amplifica announced the initiation of a clinical trial for AMP-203, indicating it is one of their lead candidate molecules derived from research into hair biology. The specific mechanism of action has not been publicly disclosed, but it is positioned as a novel therapy targeting hair growth or restoration. The primary indication under investigation is androgenetic alopecia (pattern hair loss).

Beyond the preview

Go deeper on AMP-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-203.

Explore the full profile